• The company experienced a 50% increase in its media revenues, although a considerable part of that is probably inflated by safety inventory building customers.
• Nevertheless, sooner or later, some of its 400+ customers will get FDA approved which will produce a jump in their demand for BioLife’s products.
• The acquisition strategy is the other main value builder for shareholders, but so far, the balance isn’t too positive here.

Source: Solid Quarter For BioLife, But Dilution Is A Little Concerning (NASDAQ:BLFS) | Seeking Alpha